Inovio Pharmaceuticals (INO) Depreciation & Amortization (CF) (2016 - 2026)
Inovio Pharmaceuticals' Depreciation & Amortization (CF) history spans 16 years, with the latest figure at $340197.0 for Q4 2025.
- On a quarterly basis, Depreciation & Amortization (CF) fell 26.79% to $340197.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a 21.23% decrease, with the full-year FY2025 number at $1.4 million, down 21.23% from a year prior.
- Depreciation & Amortization (CF) hit $340197.0 in Q4 2025 for Inovio Pharmaceuticals, down from $350198.0 in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for INO hit a ceiling of $940578.0 in Q2 2022 and a floor of $340197.0 in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $625895.6 across 5 years, with a median of $651005.0 in 2021.
- Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 40.67% in 2022 and later tumbled 40.65% in 2023.
- Tracing INO's Depreciation & Amortization (CF) over 5 years: stood at $905104.0 in 2021, then grew by 2.01% to $923328.0 in 2022, then tumbled by 40.65% to $548038.0 in 2023, then dropped by 15.21% to $464674.0 in 2024, then decreased by 26.79% to $340197.0 in 2025.
- Business Quant data shows Depreciation & Amortization (CF) for INO at $340197.0 in Q4 2025, $350198.0 in Q3 2025, and $356151.0 in Q2 2025.